Table 2.
Percentage of isolated strain which resulted susceptible, intermediate, or resistant to the tested antimicrobials.
| Antibiotic | Susceptible | Intermediate | Resistant |
|---|---|---|---|
| Ampicillin | 206/260 (79.2%) | 29/260 (11.2%) | 25/260 (9.6%) |
| Amoxicillin + Clavulanic Acid | 171/217 (78.8%) | 33/217 (15.2%) | 13/217 (6%) |
| Chloramphenicol | 247/251 (98.4%) | 3/251 (1.2%) | 1/251 (0.4%) |
| Cefalotin | 197/260 (75.8%) | 47/260 (18%) | 16/260 (6.2%) |
| Cefotaxime | 235/258 (91%) | 20/258 (7.8%) | 3/258 (1.2%) |
| Ciprofloxacin | 258/260 (99.2%) | 2/260 (0.8%) | 0/260 (0%) |
| Colistin | 237/245 (96.7%) | 7/245 (2.9%) | 1/245 (0.4%) |
| Ceftazidime | 195/249 (78.3%) | 52/249 (20.9%) | 2/249 (0.8%) |
| Enrofloxacin | 190/207 (91.8%) | 16/207 (7.7%) | 1/207 (0.5%) |
| Gentamicin | 223/257 (86.8%) | 27/257 (10.5%) | 7/257 (2.7%) |
| Kanamycin | 118/230 (51.3%) | 99/230 (43%) | 13/230 (5.7%) |
| Nalidixic acid | 219/253 (86.6%) | 32/253 (12.6%) | 2/253 (0.8%) |
| Streptomycin | 106/258 (41%) | 78/258 (30.2%) | 28/258 (10.8%) |
| Sulfadiazine + Sulfamerazine + Sulfamethazine | 6/248 (2.4%) | 4/248 (1.6%) | 238/248 (96%) |
| Sulfamethoxazole + Trimethoprim | 153/260 (58.8%) | 50/260 (19.2%) | 57/260 (21.9%) |
| Tetracycline | 147/260 (56.5%) | 61/260 (23.4%) | 52/260 (20%) |